Singapore Health Sciences Authority CEO John Lim On Piloting Adaptive Licensing: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Singapore could serve as a testing ground for adaptive licensing, thanks to its developed postmarketing surveillance system. But first it needs a drug candidate.
You may also be interested in...
Some ideas for new drug approval pathways seem to envision the use of Risk Evaluation and Mitigation Strategies as a means for preventing and monitoring off-label use following initial approval, apparently without regard to the seriousness or extent of a product’s risks. Given the burdens currently created by REMS, any effort to expand and retrofit the programs to a new approval pathway is likely to draw pushback from the health care community.
SINGAPORE - The spectre of a "silver tsunami," a reference to the growing elderly population, has prompted Singapore to rethink its approach to healthcare, with "total patient care" the keywords underscoring new government initiatives to address the long-term healthcare needs of its 4.8 million citizens
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?